Evidence map›Paper›PMID 41373834›Full record

ArticleInternational journal of molecular sciences2025

Benchmarking Molecular Mutation Operators for Evolutionary Drug Design.

Raúl Acosta Murillo, Patricio Adrián Zapata-Morin, José Carlos Ortiz-Bayliss

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Raúl Acosta MurilloDepartment of Microbiology and Immunology, School of Biological Sciences, Universidad Autónoma de Nuevo León, Pedro de Alba SN, San Nicolás de los Garza 66455, Nuevo Leon, Mexico.ORCID 0000-0001-7632-8131
Patricio Adrián Zapata-MorinDepartment of Microbiology and Immunology, School of Biological Sciences, Universidad Autónoma de Nuevo León, Pedro de Alba SN, San Nicolás de los Garza 66455, Nuevo Leon, Mexico.ORCID 0000-0003-1851-2293
José Carlos Ortiz-BaylissTecnologico de Monterrey, School of Engineering and Sciences, Eugenio Garza Sada 2501 Sur, Monterrey 64700, Nuevo Leon, Mexico.ORCID 0000-0003-3408-2166

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates and compares different molecular mutation strategies to optimize their application as genetic algorithm operators in drug design. We evaluated five distinct mutation methods-Graph-Based Genetic Algorithm, Graph-Based Generative Model, SmilesClickChem, SELFIES Token, and SMILES Token Mutation-by assessing their computational efficiency, validity, and impact on molecular complexity and structural conservation. Our results reveal that the Graph-Based Genetic Algorithm achieves the highest molecular validity (96.5%) while maintaining computational efficiency, making it ideal for rapid iterative drug discovery. SmilesClickChem and Graph-Based Generative Model tend to increase molecular complexity, whereas SF-T simplifies molecular structures, suggesting different applications in lead optimization. Additionally, we analyzed mutation-induced changes in pIC50 potency and found that SELFIES Token caused the most substantial shifts in bioactivity, particularly in SRC-targeted molecules. These findings underscore the importance of selecting the appropriate mutation strategy to balance validity, structural diversity, and computational cost in AI-driven drug design. Our insights help refine evolutionary algorithms for molecular generation and optimize candidate selection in early-stage drug discovery.

Indexed as

Drug DesignMutationAlgorithmsBenchmarkingDrug DiscoveryEvolution, MolecularHumanscomputer-aided drug designgenetic operatorsmolecule mutationmolecule recombination

Identifiers

PMID41373834
PMCPMC12692386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.